A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

This study is comparing a new targeted drug called SHR-A2009 to standard platinum-based chemotherapy in patients with advanced lung cancer that has a specific gene mutation (EGFR). SHR-A2009 is a type of antibody-drug conjugate, meaning it delivers chemotherapy directly to cancer cells. **You may be eligible if...** - You are 18 to 75 years old - You have advanced or metastatic non-small cell lung cancer (non-squamous type) confirmed by biopsy - Your cancer has an EGFR mutation and has already been treated with an EGFR-targeting pill (called a TKI) - Your cancer has at least one measurable tumor on scans - Your general health score (ECOG) is 0 or 1 **You may NOT be eligible if...** - Your cancer has spread to and is actively causing symptoms in the brain - You received chemotherapy or other cancer treatments within the past 4 weeks - Your organs (liver, kidneys, heart) are not functioning well enough Talk to your doctor to see if this trial is right for you.